WO1997024348A1 - ((3'-thioxacyclohex-1'-enyl))-but-3'-ene-1'-ynyl)aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity - Google Patents
((3'-thioxacyclohex-1'-enyl))-but-3'-ene-1'-ynyl)aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity Download PDFInfo
- Publication number
- WO1997024348A1 WO1997024348A1 PCT/US1996/020459 US9620459W WO9724348A1 WO 1997024348 A1 WO1997024348 A1 WO 1997024348A1 US 9620459 W US9620459 W US 9620459W WO 9724348 A1 WO9724348 A1 WO 9724348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbons
- compound
- group
- accordance
- alkyl
- Prior art date
Links
- 0 *C(C1)(C(C(*)=C(*)C#C)=C(*)SCC1N)I Chemical compound *C(C1)(C(C(*)=C(*)C#C)=C(*)SCC1N)I 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
Definitions
- the present invention is directed to novel ⁇ compounds which have retinoid-li e biological g activity. More specifically, the present invention ⁇ o relates to [ (3"-thioxacyclohexyl"-enyl) ]-but-3'-ene- ⁇ l'-ynyl]aryl and [ (3"-thioxacyclohex-l"-enyl) ]-but-
- compositions having a 7 retinoid-like compound or compounds as the active 8 ingredient are useful as regulators of cell 9 proliferation and differentiation, and particularly 0 as agents for treating skin-related diseases, 1 including, actinic keratoses, arsenic keratoses, 2 inflammatory and non-inflammatory acne, psoriasis, 3 ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Oarriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin.
- skin-related diseases 1 including, actinic keratoses, arsenic keratoses, 2 inflammatory and non-inflammatory acne, psoriasis, 3 ichthyoses and other keratinization and hyperprolifer
- Retinoid compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma.
- premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of
- retinoid compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA) .
- PVR proliferative vitreoretinopathy
- TPA tissue plasminogen activator
- retinoid compounds include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, improper ⁇ pituitary function, including insufficient
- HPV human papilloma virus
- various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease
- neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke
- improper ⁇ pituitary function including insufficient
- retinoid-like biological activity and a 4 structure wherein a phenyl and a heteroaryl or a is phenyl and a second phenyl group is linked with an i6 olephinic or acetylenic linkage.
- the present invention relates to compounds of
- R lf R 2 , R 3 , and R 4 independently are H or 2 lower alkyl of 1 to 10 carbons; s R 5 is lower alkyl of 1 to 10 carbons, fluoro, 4 chloro, bromo, iodo, nitro, or fluoroalkyl having 1 s to 10 carbons; 6 m is an integer having the value of 1 - 4; 7 n is an integer having the value of 0 - 4; 8 Y is phenyl or a heteroaryl group selected from 9 a group consisting of pyridyl, thienyl, furyl, 0 pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl and 1 oxazolyl, said Y group being optionally substituted 2 with one or more R 5 group; 3 A is (CH- j )., where p is 0-5, lower branched chain 4 alkyl having 3-6 carbons, cycl
- R X1 is lower alkyl, phenyl or
- R 12 is lower alkyl
- R 13 is
- this invention relates to
- the use of the compounds of Formula 1 for the o treatment of skin-related diseases including, i without limitation, actinic keratoses, arsenic 2 keratoses, inflammatory and non-inflammatory acne, 3 psoriasis, ichthyoses and other keratinization and 4 hyperproliferative disorders of the skin, eczema, s atopic dermatitis, Darriers disease, lichen planus, 6 prevention and reversal of glucocorticoid damage 7 (steroid atrophy), as a topical anti-microbial, as s skin anti-pigmentation agents and to treat and 9 reverse the effects of age and photo damage to the 0 skin.
- skin-related diseases including, i without limitation, actinic keratoses, arsenic 2 keratoses, inflammatory and non-inflammatory acne, 3 psoriasis, ichthyoses and other keratinization and 4 hyperproliferative disorders of the skin, e
- the compounds are also useful for the 1 prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, 5 uterus, colon, bladder, esophagus, stomach, lung, 6 larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the 9 treatment of Kaposi's sarcoma.
- premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, 5 uterus, colon, bladder, esophagus, stomach, lung, 6 larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the
- present compounds can be used as agents to treat 1 diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well 1 as in the treatment and prevention of various diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well 1 as in the treatment and prevention of various diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well 1 as in the treatment and prevention of various diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well 1 as in the treatment and prevention of various diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies,
- TPA 7 activator
- HPV human papilloma virus
- neurodegenerative diseases such as i Alzheimer's disease, Parkinson's disease and stroke, is improper pituitary function, including insufficient
- apoptosis including both the induction of apoptosis is and inhibition of T-Cell activated apoptosis,
- This invention also relates to a pharmaceutical 8 formulation comprising a compound of Formula 1 in 9 admixture with a pharmaceutically acceptable 0 excipient.
- this invention relates to 2 process for making a compound of Formula 1 which 3 process comprises:
- Formula 4 reacting a compound of Formula 2 with a compound of Formula 3 in the presence of cuprous iodide and Pd(PQ 3 )2Cl 2 (Q is phenyl) or a similar complex, giving the corresponding compound of Formula 1; or to the process of making a compound of Formula 1 which consists of reacting a zinc salt of Formula 4 with a compound of Formula 3 in the presence of Pd(PQ 3 ) 4 (Q is phenyl) or a similar complex.
- R lf R 2 , R 3 , R 4 , R 5 , Y, A, and n have the same definition as in connection with Formula 1,
- X is a halogen, preferably I
- B is H, or a protected acid, alcohol, aldehyde, or ketone
- X'" is a monovalent anion such as chloride, bromide or iodide.
- the present invention relates to the processes of homologating a compound of Formula 1 where A is (CH 2 ) n and n is 0-4 to give an acid of ⁇ Formula 1; or
- alkyl refers to and covers any and all i9 groups which are known as normal alkyl, 0 branched-chain alkyl and cycloalkyl.
- alkenyl refers to and covers normal alkenyl, branch
- lower alkyl means the 5 above-defined broad definition of alkyl groups 6 having 1 to 6 carbons, and as applicable, 3 to 6 7 carbons for branch chained and cyclo-alkyl groups.
- Lower alkenyl is defined similarly having 2 to 6 carbons for normal alkenyl, and 3 to 6 carbons for o branch chained and cycloalkenyl groups.
- esters refers to and 2 covers any compound falling within the definition of 3 that term as classically used in organic chemistry. ⁇ It includes organic and inorganic esters.
- ester is derived from compounds where B is -CH 2 OH, this term covers compounds derived from organic ⁇ acids capable of forming esters including
- a pharmaceutically acceptable salt may be ⁇ prepared for any compounds in this invention having
- 21 acceptable salt is any salt which retains the
- the salt may be a 2 ⁇ mono or polyvalent ion. Of particular interest are
- Organic salts may be made with amines,
- Preferred salts are those formed with ⁇ inorganic acids such as hydrochloric acid, sulfuric
- the compounds of the present invention contain ii at least two double bonds, and therefore have trans
- the present invention may contain one or more chiral
- the preferred 4 compounds of this invention are those where Y is 5 phenyl, pyridyl, thienyl or furyl, with the phenyl 6 and pyridyl derivatives being particularly 7 preferred.
- Y is phenyl
- compounds are 8 preferred where the ethynyl group and the A-B group 9 are attached to the 1 and 4 positions respectively o of a benzene ring (i.e., where the phenyl moiety of 1 the compound is para substituted) .
- Y group 2 is pyridyl, thienyl or furyl
- compounds are 3 preferred where the ethynyl group and the A-B group are attached to the 2 and 5 positions respectively of a pyridine ring (the 6 and 3 positions of the nicotinic acid nomenclature being equivalent to the 2/5 designation in the pyridine nomenclature) or to the 5 and 2 positions respectively of a thiophene or furan group, respectively.
- A-B side chain (substituent) on the phenyl or heteroaryl group Y compounds are preferred where A is (CH 2 ) p and p is 0.
- group B compounds are preferred where B is -C00H, an alkali metal salt or organic amine salt, or a lower alkyl ester therof.
- R x and R 3 are H or lower alkyl of 1 to 6 carbons, most preferably these groups are methyl.
- the R 2 , R 4 and R 5 groups are preferably H or lower alkyl of 1 to 6 carbons, most preferably H.
- the most preferred compounds of the invention are shown in Table 1 with reference to Formula 5.
- medicaments can be added to such topical ⁇ formulation for such secondary purposes as treating 9 skin dryness; providing protection against light; ⁇ o other medications for treating dermatoses; ii medicaments for preventing infection, reducing
- a therapeutic concentration will be that i9 concentration which effects reduction of the
- the compound potentially may be any organic compound. 21 certain instances, the compound potentially may be any organic compound.
- the e IC 60 value is that concentration of the compound (in
- the Invention is The compounds of this invention can be made by a i9 number of different synthetic chemical pathways.
- Reaction Scheme 1 ⁇ Referring now to Reaction Scheme 1 a
- a metal salt such as the zinc salt of Formula 4 i derived from the ethynyl compound of Formula 2 is 2 reacted with the reagent of Formula 3 in the s presence of a palladium complex catalyst having the 4 formula Pd(PQ 3 ) 4 (Q is phenyl) or similar complex.
- a palladium complex catalyst having the 4 formula Pd(PQ 3 ) 4 (Q is phenyl) or similar complex.
- the carboxylic acid can be condensed
- 32 group having one or more double bonds can be made 3 for example, by having the requisite number of ⁇ double bonds incorporated into the reagent of
- Such intermediate can be obtained by is reactions well known in the art, for example, by i6 reaction of a corresponding methyl ketone with
- Formula 1 are readily obtainable from the 0 corresponding esters .
- Basic saponification with an 1 alkali metal base will provide the acid.
- an ester of Formula 1 may be dissolved in a 3 polar solvent such as an alkanol, preferably under an inert atmosphere at room temperature, with about 5 a three molar excess of base, for example, potassium 6 hydroxide, sodium hydroxide or lithium hydroxide.
- the amide may be formed by any appropriate
- esters or carboxylic acids 5 corresponding esters or carboxylic acids.
- One way ⁇ to prepare such compounds is to convert an acid to 7 an acid chloride and then treat that compound with ⁇ ammonium hydroxide or an appropriate amine.
- g Alcohols are made by converting the corresponding o acids to the acid chloride with thionyl chloride or i other means (J. March, "Advanced Organic Chemistry", 2 2nd Edition, McGraw-Hill Book Company), then 3 reducing the acid chloride with sodium borohydride 4 (March, Ibid, pg. 1124), which gives the s corresponding alcohols.
- esters may 6 be reduced with lithium aluminum hydride at reduced 7 temperatures.
- Alkylating these alcohols with s appropriate alky halides under Williamson reaction 9 conditions gives the 0 corresponding ethers.
- These alcohols can be 1 converted to esters by reacting them with 2 appropriate acids in the presence of acid catalysts 3 or dicyclohexylcarbodiimide and dimethlaminopyridine.
- 5 Aldehydes can be prepared from the corresponding 6 primary alcohols using mild oxidizing agents such as 7 pyridinium dichromate in methylene chloride (Corey, ⁇ E. J., Schmidt, G., Tet. Lett.. 399, 19791.
- Ketones can be prepared from an appropriate 3 aldehyde by treating the aldehyde with an alkyl ⁇ Grignard reagent or similar reagent followed by
- the resulting solution was 9 then heated at 50°C in an oil bath for 24.5 hours, 0 concentrated in vacuo, partitioned between 200 ml of i water and 250 ml of ethyl ether, and the layers 2 were separated.
- the aqueous phase was washed with 2 3 x 150 ml-portions of ethyl ether. All organic ⁇ phases were combined, washed once with 75 ml of
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU13429/97A AU709287B2 (en) | 1995-12-29 | 1996-12-16 | ((3"-thioxacyclohex-1"-enyl))-but-3'-ene-1'-ynyl)aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity |
EP96944950A EP0877743A1 (en) | 1995-12-29 | 1996-12-16 | ((3"-thioxacyclohex-1"-enyl))-but-3'-ene-1'-ynyl)aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity |
JP9524490A JP2000502706A (en) | 1995-12-29 | 1996-12-16 | ((3 "-Thioxacyclohexa-1" -enyl))-buta-3'-en-1'-ynyl) aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/581,121 US5688957A (en) | 1995-12-29 | 1995-12-29 | (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity |
US08/581,121 | 1995-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997024348A1 true WO1997024348A1 (en) | 1997-07-10 |
Family
ID=24323974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/020459 WO1997024348A1 (en) | 1995-12-29 | 1996-12-16 | ((3'-thioxacyclohex-1'-enyl))-but-3'-ene-1'-ynyl)aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity |
Country Status (6)
Country | Link |
---|---|
US (1) | US5688957A (en) |
EP (1) | EP0877743A1 (en) |
JP (1) | JP2000502706A (en) |
AU (1) | AU709287B2 (en) |
CA (1) | CA2240401A1 (en) |
WO (1) | WO1997024348A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001007028A2 (en) * | 1999-07-23 | 2001-02-01 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264578A (en) | 1987-03-20 | 1993-11-23 | Allergan, Inc. | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
US5534641A (en) | 1994-12-29 | 1996-07-09 | Allergan | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
US5917082A (en) | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6218128B1 (en) | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5763635A (en) | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US5773594A (en) | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5741896A (en) | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5728846A (en) | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
US6313107B1 (en) | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
WO2007079394A2 (en) * | 2005-12-30 | 2007-07-12 | Revance Therapeutics, Inc. | Arginine heteromers for topical administration |
PT2056813E (en) | 2006-08-16 | 2013-08-23 | Amderma Pharmaceuticals Llc | 2,5 dihydroxybenzene compounds for the treatment of rosacea |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0176034A2 (en) * | 1984-09-22 | 1986-04-02 | BASF Aktiengesellschaft | Diaryl acetylenes, their preparation and use |
US4739098A (en) * | 1986-09-22 | 1988-04-19 | Allergan, Inc. | Ethynylphenyl-containing retinoic acid derivatives |
EP0272921A1 (en) * | 1986-12-24 | 1988-06-29 | Allergan, Inc | Ethynylheteroaromatic acids having retinoic acid-like activity |
EP0284288A1 (en) * | 1987-03-20 | 1988-09-28 | Allergan, Inc | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US4810804A (en) * | 1987-03-26 | 1989-03-07 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity |
US4923884A (en) * | 1986-12-24 | 1990-05-08 | Allergan, Inc. | Ethynylheteroaromatic-acids having retinoic acid-like activity |
US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4085091A (en) * | 1976-12-16 | 1978-04-18 | E. I. Dupont De Nemours And Company | Thermally stable, rigid polyesters from thermally stable, rigid dibasic acids and aromatic dihydroxy compounds |
US4326055A (en) * | 1977-12-22 | 1982-04-20 | Hoffmann-La Roche Inc. | Stilbene derivatives |
EP0047817A3 (en) * | 1980-08-14 | 1982-05-26 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Hydrogenated naphthalines, their preparation and application, and mixtures containing such naphthalines |
CH651034A5 (en) * | 1982-05-12 | 1985-08-30 | Hoffmann La Roche | CHROMAN, THIOCHROMAN OR 1,2,3,4-TETRAHYDROCHINOLIN DERIVATIVES AND THEIR USE AS MEDICINAL ACTIVE SUBSTANCES. |
DK158947C (en) * | 1982-07-06 | 1991-01-21 | Hoffmann La Roche | TETRAHYDRONAPHTHALIN, BENZOFURAN AND BENZOTHIOPHENDER DERIVATIVES, PREPARATION AND USE THEREOF, AND RODENTICID CONTAINING SUCH DERIVATIVES |
ATE38835T1 (en) * | 1983-07-05 | 1988-12-15 | Pfizer | CARBONIC ACID DERIVATIVES USEFUL IN PREVENTING DECOMPOSITION OF CARTILAGE. |
WO1985000806A1 (en) * | 1983-08-08 | 1985-02-28 | Sri International | Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues |
FR2562539B1 (en) * | 1984-04-06 | 1987-04-17 | Chauvin Blache Lab | NOVEL VINYL-4 BENZOIC ACID DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC APPLICATIONS THEREOF AND AS LIGANDS |
US4826984A (en) * | 1984-04-09 | 1989-05-02 | The Board Of Regents For The Oklahoma Agricultural And Mechanical College Acting For And On Behalf Of Oklahoma State University | Heteroarotinoid compounds as anticancer agents |
JPS60222445A (en) * | 1984-04-19 | 1985-11-07 | Yoshitomi Pharmaceut Ind Ltd | Phthalic acid compound |
DE3580134D1 (en) * | 1984-07-07 | 1990-11-22 | Shudo Koichi Prof Dr Chem | BENZOESAEUR DERIVATIVES. |
JPS6122046A (en) * | 1984-07-07 | 1986-01-30 | Koichi Shiyudo | Stilbene derivative |
LU85544A1 (en) * | 1984-09-19 | 1986-04-03 | Cird | AROMATIC HETEROCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE THERAPEUTIC AND COSMETIC FIELDS |
DE3434942A1 (en) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | TETRALINE DERIVATIVES, THEIR PRODUCTION AND USE |
US5256694A (en) * | 1984-09-22 | 1993-10-26 | Basf Aktiengesellschaft | Diarylacetylenes, their preparation and their use |
DE3434947A1 (en) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | ISOXAZOLIC CARBONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE |
IL80270A0 (en) * | 1985-10-11 | 1987-01-30 | Cird | Naphthalene derivatives,their preparation and pharmaceutical compositions containing them |
DE3602473A1 (en) * | 1986-01-28 | 1987-07-30 | Basf Ag | VINYLPHENOL DERIVATIVES, THEIR PRODUCTION AND USE |
LU86351A1 (en) * | 1986-03-12 | 1987-11-11 | Oreal | BENZOPYRANNYL AND BENZOTHIOPYRANNYL BENZOIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN COSMETICS AND HUMAN AND VETERINARY MEDICINE |
DE3615157A1 (en) * | 1986-05-05 | 1987-11-12 | Schwabe Willmar Gmbh & Co | 5-ARYLALKYL-4-ALKOXY-2 (5H) -FURANONE, INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS THERAPEUTIC ACTIVE SUBSTANCES |
ZW6587A1 (en) * | 1986-05-13 | 1987-12-02 | Hoffmann La Roche | Tetrahydro naphthanline derivatives |
ZW7487A1 (en) * | 1986-05-23 | 1987-12-16 | Hoffmann La Roche | Tetrahydronaphthaline and indane derivatives |
ZW10287A1 (en) * | 1986-07-15 | 1988-01-13 | Hoffmann La Roche | Tetrahydronaphthaline and indane derivatives |
US4927947A (en) * | 1986-12-24 | 1990-05-22 | Allergan, Inc. | Ethynylheteroaromatic-acids having retinoic acid-like activity |
US5264578A (en) * | 1987-03-20 | 1993-11-23 | Allergan, Inc. | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
US5234926A (en) * | 1987-03-20 | 1993-08-10 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
ZA885192B (en) * | 1987-08-19 | 1989-04-26 | Hoffmann La Roche | Pharmaceutical preparations |
CA1298309C (en) * | 1987-11-06 | 1992-03-31 | Michael Klaus | Benzocycloheptene derivatives |
KR0139216B1 (en) * | 1988-04-11 | 1998-05-01 | 제임스 엠. 캐내지 | Tetralin esters of phenols or benzoic acids having retinoic like activity |
US5231113A (en) * | 1988-04-11 | 1993-07-27 | Allergan, Inc. | Tetralin esters of phenols or benzoic acids having retinoid like activity |
US4895868A (en) * | 1988-06-29 | 1990-01-23 | Allergan, Inc. | Thiochroman esters of phenols and terephthallates having retinoid-like activity |
US5015658A (en) * | 1988-06-29 | 1991-05-14 | Allergan, Inc. | Thiochroman esters of phenols and terephthallates having retinoid-like activity |
AU626881B2 (en) * | 1988-07-14 | 1992-08-13 | F. Hoffmann-La Roche Ag | Benzofused heterocyclics used as pharmaceuticals |
US4992468A (en) * | 1989-07-26 | 1991-02-12 | Allergan, Inc. | Phenylethenyl compounds having retinoid-like activity |
US5068252A (en) * | 1989-07-26 | 1991-11-26 | Allergan, Inc. | Methods of using phenylethenyl compounds having retinoid-like activity |
US5045551A (en) * | 1989-09-19 | 1991-09-03 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5248777A (en) * | 1989-09-19 | 1993-09-28 | Allergan, Inc. | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity |
US5183827A (en) * | 1989-09-19 | 1993-02-02 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5272156A (en) * | 1989-09-19 | 1993-12-21 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5399561A (en) * | 1989-09-19 | 1995-03-21 | Allergan, Inc. | Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity |
US4980369A (en) * | 1989-09-19 | 1990-12-25 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity |
US5162546A (en) * | 1989-09-19 | 1992-11-10 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5053523A (en) * | 1989-09-19 | 1991-10-01 | Allergan, Inc. | Ethynyl-chroman compounds |
US5023341A (en) * | 1989-09-19 | 1991-06-11 | Allergan, Inc. | Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity |
US5005550A (en) * | 1989-12-19 | 1991-04-09 | Chrysler Corporation | Canister purge for turbo engine |
US5013744B1 (en) * | 1989-12-29 | 1994-09-20 | Allegran Inc | Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity |
US5264456A (en) * | 1989-12-29 | 1993-11-23 | Allergan, Inc. | Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity |
US5175185A (en) * | 1989-12-29 | 1992-12-29 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity |
US5202471A (en) * | 1990-02-06 | 1993-04-13 | Allergan, Inc. | Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity |
CA2080581A1 (en) * | 1990-04-16 | 1991-10-17 | Alfred P. Spada | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase |
LU87821A1 (en) * | 1990-10-12 | 1992-05-25 | Cird Galderma | BI-AROMATIC COMPOUNDS, AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS |
EP0571546B1 (en) * | 1991-02-13 | 1996-10-16 | Allergan, Inc. | Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity |
US5134159A (en) * | 1991-03-26 | 1992-07-28 | Allergan, Inc. | 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity |
JP3157523B2 (en) * | 1991-03-26 | 2001-04-16 | アラーガン、インコーポレイテッド | Chromans and thiochromans having a heteroarylethynyl substituent at position 7 with retinoid-like biological activity |
US5326898A (en) * | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
CA2129831A1 (en) * | 1992-02-11 | 1993-08-19 | Roshantha A. S. Chandraratna | Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity |
US5324840A (en) * | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5399586A (en) * | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
US5344959A (en) * | 1993-05-18 | 1994-09-06 | Allergan, Inc. | Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity |
US5475022A (en) * | 1993-10-18 | 1995-12-12 | Allergan, Inc. | Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity |
US5470999A (en) * | 1993-12-30 | 1995-11-28 | Allergan, Inc. | Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity |
US5451605A (en) * | 1993-12-30 | 1995-09-19 | Allergan, Inc. | 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity |
US5426118A (en) * | 1993-12-30 | 1995-06-20 | Allergan, Inc. | [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity |
CA2138000A1 (en) * | 1994-01-03 | 1995-07-04 | John E. Starrett, Jr. | Retinoid-like compounds |
US5498755A (en) * | 1994-08-23 | 1996-03-12 | Chandraratna; Roshantha A. | Disubstituted aryl and heteroaryl imines having retinoid-like biological activity |
US5489584A (en) * | 1994-12-29 | 1996-02-06 | Allergan, Inc. | Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5498795A (en) * | 1994-12-29 | 1996-03-12 | Allergan, Inc. | Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
US5543534A (en) * | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
-
1995
- 1995-12-29 US US08/581,121 patent/US5688957A/en not_active Expired - Fee Related
-
1996
- 1996-12-16 JP JP9524490A patent/JP2000502706A/en active Pending
- 1996-12-16 EP EP96944950A patent/EP0877743A1/en not_active Withdrawn
- 1996-12-16 AU AU13429/97A patent/AU709287B2/en not_active Ceased
- 1996-12-16 WO PCT/US1996/020459 patent/WO1997024348A1/en not_active Application Discontinuation
- 1996-12-16 CA CA002240401A patent/CA2240401A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0176034A2 (en) * | 1984-09-22 | 1986-04-02 | BASF Aktiengesellschaft | Diaryl acetylenes, their preparation and use |
US4739098A (en) * | 1986-09-22 | 1988-04-19 | Allergan, Inc. | Ethynylphenyl-containing retinoic acid derivatives |
EP0272921A1 (en) * | 1986-12-24 | 1988-06-29 | Allergan, Inc | Ethynylheteroaromatic acids having retinoic acid-like activity |
US4923884A (en) * | 1986-12-24 | 1990-05-08 | Allergan, Inc. | Ethynylheteroaromatic-acids having retinoic acid-like activity |
EP0284288A1 (en) * | 1987-03-20 | 1988-09-28 | Allergan, Inc | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US4810804A (en) * | 1987-03-26 | 1989-03-07 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity |
US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001007028A2 (en) * | 1999-07-23 | 2001-02-01 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
WO2001007028A3 (en) * | 1999-07-23 | 2001-08-30 | Allergan Sales Inc | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
Also Published As
Publication number | Publication date |
---|---|
JP2000502706A (en) | 2000-03-07 |
US5688957A (en) | 1997-11-18 |
AU1342997A (en) | 1997-07-28 |
CA2240401A1 (en) | 1997-07-10 |
EP0877743A1 (en) | 1998-11-18 |
AU709287B2 (en) | 1999-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5489584A (en) | Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | |
US5648503A (en) | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | |
US5514825A (en) | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | |
US6355806B1 (en) | Acetylenes disubstituted with a 5 alkyl, aryl or heteroaryl substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like with an aryl or heteroaryl group having retinoid-like biological activity | |
US5470999A (en) | Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity | |
EP0436398B1 (en) | Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity | |
EP0419131B1 (en) | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity | |
US5616712A (en) | Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity | |
US5399561A (en) | Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity | |
US5618943A (en) | Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | |
US5723620A (en) | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity | |
US5688957A (en) | (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity | |
EP0419130B1 (en) | Acetylenes disubstituted with a heteroaromatic group and A 2-substituted chromanyl, thiochromanyl or 1,2,3,4- tetrahydroquinolinyl group having retinoid-like activity | |
AU610567B2 (en) | Acetylenes disubstituted with a heteroaromatic group and a tetralin group having retinoid like activity | |
US5677323A (en) | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1, 2, 3, 4, -tetrahydroquinolinyl group having retinoid-like activity | |
US5516904A (en) | Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity | |
US5602130A (en) | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | |
US5451605A (en) | 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity | |
US5618931A (en) | Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | |
US5556996A (en) | Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity | |
WO1993016067A1 (en) | Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity | |
WO1996020938A1 (en) | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2240401 Country of ref document: CA Ref country code: CA Ref document number: 2240401 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996944950 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996944950 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996944950 Country of ref document: EP |